Allakos announced that the first patient with chronic spontaneous urticaria has been dosed in a randomized, double-blind, placebo-controlled Phase 1 trial of AK006. The Phase 1 trial is designed to assess the safety, tolerability and pharmacokinetics of AK006, and to explore the therapeutic effects of AK006 in patients with CSU using the urticaria activity score at 14 weeks. Top-line results from the trial are expected at year end 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLK:
Questions or Comments about the article? Write to editor@tipranks.com